X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DR. REDDYS LAB - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DR. REDDYS LAB DIVIS LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x 30.8 34.5 89.4% View Chart
P/BV x 5.3 3.4 157.9% View Chart
Dividend Yield % 0.9 0.8 116.1%  

Financials

 DIVIS LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
DR. REDDYS LAB
Mar-17
DIVIS LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2223,397 36.0%   
Low Rs7842,560 30.6%   
Sales per share (Unadj.) Rs153.1856.5 17.9%  
Earnings per share (Unadj.) Rs39.978.0 51.2%  
Cash flow per share (Unadj.) Rs44.6139.9 31.9%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.00.7 148.5%  
Book value per share (Unadj.) Rs201.8739.8 27.3%  
Shares outstanding (eoy) m265.47165.74 160.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x6.63.5 188.4%   
Avg P/E ratio x25.138.2 65.7%  
P/CF ratio (eoy) x22.521.3 105.7%  
Price / Book Value ratio x5.04.0 123.5%  
Dividend payout %25.025.7 97.6%   
Avg Mkt Cap Rs m266,266493,632 53.9%   
No. of employees `0009.722.7 42.9%   
Total wages/salary Rs m4,68731,068 15.1%   
Avg. sales/employee Rs Th4,175.06,259.0 66.7%   
Avg. wages/employee Rs Th481.51,369.8 35.2%   
Avg. net profit/employee Rs Th1,089.3569.7 191.2%   
INCOME DATA
Net Sales Rs m40,643141,961 28.6%  
Other income Rs m7491,715 43.7%   
Total revenues Rs m41,392143,676 28.8%   
Gross profit Rs m14,46024,722 58.5%  
Depreciation Rs m1,23310,266 12.0%   
Interest Rs m23634 3.6%   
Profit before tax Rs m13,95315,537 89.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3492,965 113.0%   
Profit after tax Rs m10,60412,921 82.1%  
Gross profit margin %35.617.4 204.3%  
Effective tax rate %24.019.1 125.8%   
Net profit margin %26.19.1 286.7%  
BALANCE SHEET DATA
Current assets Rs m40,10596,837 41.4%   
Current liabilities Rs m6,59584,199 7.8%   
Net working cap to sales %82.58.9 926.2%  
Current ratio x6.11.2 528.8%  
Inventory Days Days11973 161.6%  
Debtors Days Days8198 82.6%  
Net fixed assets Rs m19,995102,552 19.5%   
Share capital Rs m531829 64.0%   
"Free" reserves Rs m53,043121,792 43.6%   
Net worth Rs m53,574122,621 43.7%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m61,585218,165 28.2%  
Interest coverage x618.425.5 2,424.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.7 101.4%   
Return on assets %17.36.2 277.7%  
Return on equity %19.810.5 187.8%  
Return on capital %26.112.9 202.2%  
Exports to sales %054.6 0.0%   
Imports to sales %25.29.4 270.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs m10,25913,274 77.3%   
Fx inflow Rs m35,38481,670 43.3%   
Fx outflow Rs m10,39926,355 39.5%   
Net fx Rs m24,98555,315 45.2%   
CASH FLOW
From Operations Rs m11,49321,444 53.6%  
From Investments Rs m-11,372-18,404 61.8%  
From Financial Activity Rs m-93-3,692 2.5%  
Net Cashflow Rs m28-1,144 -2.5%  

Share Holding

Indian Promoters % 52.0 25.5 203.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.4 218.5%  
FIIs % 19.0 35.3 53.8%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.2 15.3 112.4%  
Shareholders   31,796 75,885 41.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 22, 2018 03:33 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS